Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of Kiacta in AA amyloidosis with renal involvement
NL-OMON39822Phase 3Active, not recruiting
- Sponsor
- Auven Therapeutics
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in AA amyloidosis comparing Kiacta with Placebo (2 arms). Primary endpoints: Time to composite renal endpoint and Safety. Started Feb 2012; status: active, not recruiting.
02
Drugs
eprodisate
03
Conditions
AA amyloidosis
Beyond the preview
Go deeper on NL-OMON39822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39822.